Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis
Autore:
Ossege, LM; Sindern, E; Patzold, T; Malin, JP;
Indirizzi:
Ruhr Univ Bochum, Dept Neurol, BG Kliniken Bergmannsheil, D-44789 Bochum, Germany Ruhr Univ Bochum Bochum Germany D-44789 nnsheil, D-44789 Bochum, Germany
Titolo Testata:
INTERNATIONAL IMMUNOPHARMACOLOGY
fascicolo: 6, volume: 1, anno: 2001,
pagine: 1085 - 1100
SICI:
1567-5769(200106)1:6<1085:IEOIIP>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRANSFORMING GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; SUPPRESSOR-CELL-FUNCTION; BLOOD MONONUCLEAR-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MESSENGER-RNA EXPRESSION; FACTOR-BETA; FACTOR-ALPHA; CEREBROSPINAL-FLUID; ADHESION MOLECULE-1;
Keywords:
multiple sclerosis; interferon-beta-1b; immunomodulatory therapy; TGF beta-1; TGF beta beta receptor type II; TNF alpha; TNF alpha receptor type I; soluble vascular adhesion molecule-1; lymphocyte subsets;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
83
Recensione:
Indirizzi per estratti:
Indirizzo: Ossege, LM Ruhr Univ Bochum, Dept Neurol, BG Kliniken Bergmannsheil, D-44789 Bochum, Germany Ruhr Univ Bochum Bochum Germany D-44789 44789 Bochum, Germany
Citazione:
L.M. Ossege et al., "Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis", INT IMMUNO, 1(6), 2001, pp. 1085-1100

Abstract

The mechanisms by which IFN beta -lb acts in the treatment of patients with multiple sclerosis (MS) are not completely known. Immunomodulatoly effects of IFN beta -1b were investigated in patients with relapsing-remitting (RR) MS in vivo and in vitro. Compared to baseline and controls, defined as patients with RR-MS without immunomodulatory therapy, the expression of TGF beta -1-mRNA by peripheral blood mononuclear cells (PBMC) was persistently increased at week 6, month 3 and month 6 (p less than or equal to 0.05), that of the TGF beta -1 receptor type II from day 5 up to month 6 (p < 0.01). The expression of TNF alpha -mRNA decreased from day 1 to month 3 comparedto day 0 and the controls (p < 0.01). The in vitro investigations performed on isolated peripheral blood lymphocytes demonstrated that these effects were dose-dependent. The mRNA and protein expression of TNF alpha -R-I (55kD-receptor) was only temporarily elevated at the beginning of the therapy in vivo. The expression of TNF alpha -R-I-mRNA increased dose-dependently after stimulation with IFN beta -1b for 24 h in vitro. Serum levels of soluble vascular cell adhesion molecule (sVCAM) were increased during the whole time of in vivo treatment (p < 0.01). The CD8CD38 lymphocyte subpopulation was continuously elevated from day 5 up to month 6 (p < 0.01) in the MS patients treated with IFN beta -1b in vivo. No persistent, significant changes were demonstrable concerning the percentage of total CD4, CD8, CD19 nor in CD4 subpopulations (CD4CD29, CD4CD45RA). The present data suggest that IFN beta -1b induces the mRNA expression of TGF beta -1 and TGF beta -R-II by PBMC, decreases that of TNF alpha and increases levels of sVCAM-1 and of circulating activated CD8 cells (CD8CD38) in blood. These might be other mechanisms by which IFN beta -1b mediates its positive effects in the treatment of MS patients. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/21 alle ore 02:39:45